Skip to main content

Research Repository

Advanced Search

Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial

Phoa, K. Nadine; van Vilsteren, Frederike G.I.; Weusten, Bas L.A.M.; Bisschops, Raf; Schoon, Erik J.; Raganuth, Krish; Fullarton, Grant; Di Pietro, Massimiliano; Ravi, Narayanasamy; Visser, Mike; Offerhaus, G. Johan; Seldenrijk, Cees A.; Meijer, Sybren L.; ten Kate, Fiebo J.W.; Tijssen, Jan G.P.; Bergman, Jacques J.G.H.M.

Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial Thumbnail


Authors

K. Nadine Phoa

Frederike G.I. van Vilsteren

Bas L.A.M. Weusten

Raf Bisschops

Erik J. Schoon

Krish Raganuth

Grant Fullarton

Massimiliano Di Pietro

Narayanasamy Ravi

Mike Visser

G. Johan Offerhaus

Cees A. Seldenrijk

Sybren L. Meijer

Fiebo J.W. ten Kate

Jan G.P. Tijssen

Jacques J.G.H.M. Bergman



Abstract

Importance
Barrett esophagus containing low-grade dysplasia is associated with an increased risk of developing esophageal adenocarcinoma, a cancer with a rapidly increasing incidence in the western world.

Objective
To investigate whether endoscopic radiofrequency ablation could decrease the rate of neoplastic progression.

Design, Setting, and Participants
Multicenter randomized clinical trial that enrolled 136 patients with a confirmed diagnosis of Barrett esophagus containing low-grade dysplasia at 9 European sites between June 2007 and June 2011. Patient follow-up ended May 2013.

Interventions
Eligible patients were randomly assigned in a 1:1 ratio to either endoscopic treatment with radiofrequency ablation (ablation) or endoscopic surveillance (control). Ablation was performed with the balloon device for circumferential ablation of the esophagus or the focal device for targeted ablation, with a maximum of 5 sessions allowed.

Main Outcomes and Measures
The primary outcome was neoplastic progression to high-grade dysplasia or adenocarcinoma during a 3-year follow-up since randomization. Secondary outcomes were complete eradication of dysplasia and intestinal metaplasia and adverse events.

Results
Sixty-eight patients were randomized to receive ablation and 68 to receive control. Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0% (1.5% for ablation vs 26.5% for control; 95% CI, 14.1%-35.9%; P?

Citation

Phoa, K. N., van Vilsteren, F. G., Weusten, B. L., Bisschops, R., Schoon, E. J., Raganuth, K., Fullarton, G., Di Pietro, M., Ravi, N., Visser, M., Offerhaus, G. J., Seldenrijk, C. A., Meijer, S. L., ten Kate, F. J., Tijssen, J. G., & Bergman, J. J. (2014). Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial. Journal of the American Medical Association, 311(12), 1209-1217. https://doi.org/10.1001/jama.2014.2511

Journal Article Type Article
Acceptance Date Feb 28, 2014
Online Publication Date Mar 26, 2014
Publication Date Mar 26, 2014
Deposit Date Feb 12, 2018
Publicly Available Date Dec 16, 2020
Journal Journal of the American Medical Association
Print ISSN 0098-7484
Electronic ISSN 1538-3598
Publisher American Medical Association
Peer Reviewed Peer Reviewed
Volume 311
Issue 12
Pages 1209-1217
DOI https://doi.org/10.1001/jama.2014.2511
Public URL https://nottingham-repository.worktribe.com/output/1118264
Publisher URL https://jamanetwork.com/article.aspx?doi=10.1001/jama.2014.2511
PMID 24668102

Files





Downloadable Citations